Geographic Atrophy Clinical Trials in Sacramento, California
7 recruitingSacramento, California
Showing 1–7 of 7 trials
Recruiting
Phase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Age related macular degeneration (AMD)Geographic Atrophy (GA)
ONL Therapeutics324 enrolled53 locationsNCT06659445
Recruiting
Phase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Geographic Atrophy
Genentech, Inc.60 enrolled17 locationsNCT05626114
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled218 locationsNCT06541704
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled51 locationsNCT07441642
Recruiting
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.500 enrolled65 locationsNCT06779773
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic Atrophy
Hoffmann-La Roche132 enrolled16 locationsNCT06961370
Recruiting
Phase 1Phase 2
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Geographic AtrophyAge-Related Macular DegenerationNon-neovascular AMD
Perceive Biotherapeutics, Inc.60 enrolled11 locationsNCT06087458